SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
A subset of individuals who recover from coronavirus disease 2019 (COVID-19) develop post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC), but the mechanistic basis of PASC-associated lung abnormalities suffers from a lack of longitudinal tissue samples. The mouse-adapted SARS-CoV-2 strain MA10 produces an acute respiratory distress syndrome in mice similar to humans. To investigate PASC pathogenesis, studies of MA10-infected mice were extended from acute to clinical recovery phases. At 15 to 120 days after virus clearance, pulmonary histologic findings included subpleural lesions composed of collagen, proliferative fibroblasts, and chronic inflammation, including tertiary lymphoid structures. Longitudinal spatial transcriptional profiling identified global reparative and fibrotic pathways dysregulated in diseased regions, similar to human COVID-19. Populations of alveolar intermediate cells, coupled with focal up-regulation of profibrotic markers, were identified in persistently diseased regions. Early intervention with antiviral EIDD-2801 reduced chronic disease, and early antifibrotic agent (nintedanib) intervention modified early disease severity. This murine model provides opportunities to identify pathways associated with persistent SARS-CoV-2 pulmonary disease and test countermeasures to ameliorate PASC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Science translational medicine - 14(2022), 664 vom: 28. Sept., Seite eabo5070 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dinnon, Kenneth H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 30.09.2022 Date Revised 16.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/scitranslmed.abo5070 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343776979 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343776979 | ||
| 003 | DE-627 | ||
| 005 | 20231226021233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/scitranslmed.abo5070 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343776979 | ||
| 035 | |a (NLM)35857635 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dinnon, Kenneth H |c 3rd |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2022 | ||
| 500 | |a Date Revised 16.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A subset of individuals who recover from coronavirus disease 2019 (COVID-19) develop post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC), but the mechanistic basis of PASC-associated lung abnormalities suffers from a lack of longitudinal tissue samples. The mouse-adapted SARS-CoV-2 strain MA10 produces an acute respiratory distress syndrome in mice similar to humans. To investigate PASC pathogenesis, studies of MA10-infected mice were extended from acute to clinical recovery phases. At 15 to 120 days after virus clearance, pulmonary histologic findings included subpleural lesions composed of collagen, proliferative fibroblasts, and chronic inflammation, including tertiary lymphoid structures. Longitudinal spatial transcriptional profiling identified global reparative and fibrotic pathways dysregulated in diseased regions, similar to human COVID-19. Populations of alveolar intermediate cells, coupled with focal up-regulation of profibrotic markers, were identified in persistently diseased regions. Early intervention with antiviral EIDD-2801 reduced chronic disease, and early antifibrotic agent (nintedanib) intervention modified early disease severity. This murine model provides opportunities to identify pathways associated with persistent SARS-CoV-2 pulmonary disease and test countermeasures to ameliorate PASC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Leist, Sarah R |e verfasserin |4 aut | |
| 700 | 1 | |a Okuda, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Fritch, Ethan J |e verfasserin |4 aut | |
| 700 | 1 | |a Gully, Kendra L |e verfasserin |4 aut | |
| 700 | 1 | |a De la Cruz, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Evangelista, Mia D |e verfasserin |4 aut | |
| 700 | 1 | |a Asakura, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Gilmore, Rodney C |e verfasserin |4 aut | |
| 700 | 1 | |a Hawkins, Padraig |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Satoko |e verfasserin |4 aut | |
| 700 | 1 | |a West, Ande |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gralinski, Lisa E |e verfasserin |4 aut | |
| 700 | 1 | |a Everman, Jamie L |e verfasserin |4 aut | |
| 700 | 1 | |a Sajuthi, Satria P |e verfasserin |4 aut | |
| 700 | 1 | |a Zweigart, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a McBride, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Cooley, Michelle R |e verfasserin |4 aut | |
| 700 | 1 | |a Hines, Jesse B |e verfasserin |4 aut | |
| 700 | 1 | |a Love, Miriya K |e verfasserin |4 aut | |
| 700 | 1 | |a Groshong, Steve D |e verfasserin |4 aut | |
| 700 | 1 | |a VanSchoiack, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Phelan, Stefan J |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Hether, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Zumwalt, Ross E |e verfasserin |4 aut | |
| 700 | 1 | |a Barton, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Duval, Eric J |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Stroberg, Edana |e verfasserin |4 aut | |
| 700 | 1 | |a Borczuk, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Thorne, Leigh B |e verfasserin |4 aut | |
| 700 | 1 | |a Sakthivel, Muthu K |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yueh Z |e verfasserin |4 aut | |
| 700 | 1 | |a Hagood, James S |e verfasserin |4 aut | |
| 700 | 1 | |a Mock, Jason R |e verfasserin |4 aut | |
| 700 | 1 | |a Seibold, Max A |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neal, Wanda K |e verfasserin |4 aut | |
| 700 | 1 | |a Montgomery, Stephanie A |e verfasserin |4 aut | |
| 700 | 1 | |a Boucher, Richard C |e verfasserin |4 aut | |
| 700 | 1 | |a Baric, Ralph S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science translational medicine |d 2009 |g 14(2022), 664 vom: 28. Sept., Seite eabo5070 |w (DE-627)NLM195151879 |x 1946-6242 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:664 |g day:28 |g month:09 |g pages:eabo5070 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/scitranslmed.abo5070 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 664 |b 28 |c 09 |h eabo5070 | ||